Pomerantz LLP is investigating Karyopharm Therapeutics for possible securities fraud related to a recent announcement of large cash retention awards for top executives. Following the disclosure of retention bonuses ranging from $625,000 to $1.725 million, Karyopharm's stock price fell by over 21%. The investigation will determine if the company or its officers engaged in unlawful business practices. Investors affected by the stock drop may join a class action lawsuit as the case develops.
Argus Research increased its price target for NetApp to $225, citing a 13.5% potential upside from the current price of $198.18. NetApp reported strong fiscal Q1 2027 results with revenues up 29.9% to over $2 billion and non-GAAP EPS rising 66.5% to ...
New Jersey American Water received approval for rate increases that will add $68 million annually to its revenue. This funding supports over $1.4 billion in critical infrastructure upgrades, including replacing aging water mains and improving treatme...
MoneyHero Limited reported Q3 2026 earnings with an EPS of -$0.03 and revenue of $15.75 million, missing analyst estimates. The company is shifting strategy to offer more cash rewards to attract users, which has lowered immediate revenue and resulted...
Hooker Furnishings reported Q2 fiscal 2027 earnings of $0.11 per share from continuing operations, beating analyst expectations of a $0.02 loss per share, while total diluted EPS including discontinued operations was $0.15. However, quarterly net sal...
Salesforce received a Buy rating and $275 price target from Stifel Nicolaus, reflecting a potential 10.88% upside from its current price of $248. The upgrade follows strong Q2 results and growing confidence in Salesforce's AI initiatives, including i...
